A new study by researchers from the University of Sao Paulo (USP) has identified crucial proteins and signalling pathways involved in the effectiveness of CAR-T cell immunotherapy used to treat blood cancers.

The findings provide new insights that could enhance the clinical success of this innovative therapy, as reported by TV Cultura, a partner of TV BRICS.

Experts claimed CAR-T cell therapy represents a breakthrough in the treatment of haematological malignancies, offering new hope to patients with forms of cancer that are resistant to conventional treatments.

The USP team systematically investigated molecular effectors, primarily proteins, that are involved in cellular responses to CAR-T therapy. The researchers identified key proteins that play a central role in immune signalling and cellular processes related to therapy effectiveness.

These molecular effectors may serve as potential targets for future therapeutic strategies, helping to optimise and personalise CAR-T cell treatments.

African Times published this article in partnership with International Media Network TV BRICS